Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilars and to the discovery and development of novel therapeutics for autoimmune indications. In July 2010, Momentaâs lead product (developed in collaboration with Sandoz) was approved as the first generic version of LOVENOXÂŽ (Enoxaparin Sodium Injection). In April 2015, the company announced the FDA approval of once daily GlatopaÂŽ 20 mg/mL (glatiramer acetate injection), a fully substitutable generic version of COPAXONEÂŽ 20 mg/mL. Glatopa was also developed in collaboration with Sandoz. The company's development pipeline includes a biosimilar version of HUMIRAÂŽ (adalimumab), a biosimilar version of ORENCIAÂŽ (abatacept) and a portfolio of five other early stage biosimilar programs in collaboration with Mylan and three novel drug candidates for autoimmune indications. Source
No articles found.
CollPlant is a regenerative medicine company focused on 3D bioprinting of tissues ...
CollPlant is a regenerative medicine company fo...
Quanterix is a company that is digitizing biomarker analysis with the goal of adva...
Quanterix is a company that is digitizing bioma...
So-Young International Inc. (NASDAQ: SY) (âSo-Youngâ or the âCompanyâ) is ...
So-Young International Inc. (NASDAQ: SY) (âSo...
Morphic Therapeutic is leading the development of a new generation of oral integri...
Morphic Therapeutic is leading the development ...
Conatus Pharmaceuticals is a biotechnology company focused on the development and ...
Conatus Pharmaceuticals is a biotechnology comp...
Titan is a specialty pharmaceuticals company that develops therapeutics for select...
Titan is a specialty pharmaceuticals company th...
We are a biotechnology company developing novel immunotherapy treatments for cance...
We are a biotechnology company developing novel...
Join the National Investor Network and get the latest information with your interests in mind.